Human T-lymphotropic virus type-1 (HTLV-1) is a cause of T-cell leukemia/lymphoma as well as severe autoimmune disorders. An estimated 5-10 million individuals are infected globally, with Indigenous populations in central Australia most highly affected. Using the second-generation molecular Clamp platform, we seek to develop a candidate HTLV-1 glycoprotein vaccine using the Molecular Clamp and utilise this antigen to discover neutralising monoclonal antibodies as potential therapeutic agents.

Patents

Chimeric molecules and uses thereof https://patents.google.com/patent/WO2018176103A1/en

Key publications

Coming soon…

Project members

Associate Professor Keith Chappell

Group Leader
Chappell Group

Dr Jake O’Donnell

Postdoctoral research Fellow
Chappell Group

Dr Noushin Jaberolansar

Research Fellow
Chappell group